

## **Referenzen**

1. Khan AA et al. Efficacy and Safety of Palopegteripatide Treatment in Adults With Hypoparathyroidism: 3-Year Results From the Phase 3 PaTHway Trial. Endocrine Society Annual Meeting (ENDO) 2025, San Francisco, California.

## **Hinweise**

**HypoPT** = Hypoparathyreoidismus